AUSTIN, Texas–(BUSINESS WIRE)–Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial exploring PIKTOR in advanced endometrial cancer. To register, click here. The event will feature key opinion leader and PIK-201 principal investigator David Star
